EU has achieved much in pandemic preparedness, but more still to be done

5 March 2007

The European Union and its member states have made major progress in preparing against an influenza pandemic - but they still have at least two more years of work to do, concludes a report prepared for the European Commission by the European Center for Disease Prevention and Control (ECDC).

The report says that additional efforts need to be made in areas such as: consistency of planning across all government departments; implementation at local level; coordination at European level; research on influenza; and response to seasonal influenza. The report has been prepared with information and input from the 25 countries which were EU member states in 2006, plus Iceland and Norway. A further progress report is planned for late 2007.

Commenting on the conclusions, ECDC Director Zsuzsanna Jakab said: "since 2005 health authorities across the EU have put major efforts into improving their preparedness against a pandemic. This has been an almost unprecedented response against a threat that has yet to come. The challenge now is for governments and EU bodies to sustain the momentum for a further two or three years, to do the work identified in this report. If this is done, then EU countries will be in a position to respond well to a pandemic."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight